Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: Importance of sequential dermoscopy

Archives of Dermatology

Volumn 148, Issue 10, 2012, Pages 1183-1185

  Haenssle, Holger A ^a   Kraus, Sophie L ^a   Brehmer, Franziska ^a   Kretschmer, Lutz ^a   Völker, Bernward ^b   Asper, Hiba ^c   Kapp, Alexander ^c   Gutzmer, Ralf ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b NORDSTADT HOSPITAL   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; VEMURAFENIB;

ADULT; ARTICLE; BRAF GENE; CASE REPORT; CLINICAL FEATURE; DIGITAL IMAGING; DISEASE CLASSIFICATION; EPILUMINESCENCE MICROSCOPY; FEMALE; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MELANOCYTIC NEVUS; MELANOMA SKIN CANCER; METASTASIS POTENTIAL; PRIORITY JOURNAL; PYROSEQUENCING; SKIN DEFECT; TREATMENT OUTCOME;

EID: 84867649483     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2012.2649     Document Type: Article

References (9)

1. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
4. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol. 2012;30(3):316-321.
5. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207-215.
6. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19-20. (Pubitemid 36068675)
7. Zalaudek I, Guelly C, Pellacani G, et al. The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations. J Invest Dermatol. 2011;131(2):542-545.
8. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365(15):1448-1449.
9. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;22(11):33-44.